What is Iovance Biotherapeutics, Inc.'s total revenue?

Iovance Biotherapeutics, Inc. (IOVA) reported total revenue of $71.43M in Q1 2026.

How has Iovance Biotherapeutics, Inc.'s total revenue changed year-over-year?

Iovance Biotherapeutics, Inc.'s total revenue increased by 44.8% year-over-year, from $49.32M to $71.43M.

What is the long-term trend for Iovance Biotherapeutics, Inc.'s total revenue?

Over 2 years (2023 to 2025), Iovance Biotherapeutics, Inc.'s total revenue has grown at a 1388.7% compound annual growth rate (CAGR), from $1.19M to $263.5M.

What does total revenue mean?

The aggregate of all revenue from the company's operations — the top line from which all profitability metrics are derived.

Iovance Biotherapeutics, Inc. IOVA Total Revenue

Total Revenue at other companies

Bristol-Myers SquibbBMY

$11.49B+2.6%

Gilead SciencesGILD

$6.96B+4.4%

ImmunomeIMNM

$0-100%

Nuvation BioNUVB

$83.23M+2,599%

ImmunityBio, Inc.IBRX

$44.21M+168%

Viridian Therapeutics, Inc.VRDN

$141K+95.8%

Segments

By product

See full

Amtagvi$60.22M+38.2%

Proleukin$11.21M+94.8%

By segment

See full

Single Reportable$71.43M+44.8%

By geography

See full

US$48.52M—

Other financials

Income statement

See full

Gross profit$28.9M+338%

Operating income-$81.0M+33.1%

Net income-$79.0M+32.0%

EPS (diluted)-$0.19+47.2%

Balance sheet

See full

Cash & equivalents$196.5M+14.5%

Total debt$46.8M-11.3%

Total equity$721.8M-6.0%

Total assets$925.7M-4.2%

Cash flow

See full

Operating cash flow-$72.1M+30.5%

CapEx$6.6M+6.4%

Free cash flow-$78.7M+28.4%

Valuation

See full

Market cap$1.98B+32.4%

Enterprise value$1.83B+33.2%

P/S6.9×-0.1×

Profitability

See full

Gross margin36.7%+4.1pp

Operating margin-127.2%-31.0pp

Net margin-123.9%-28.4pp

FCF margin-106.8%-27.5pp

Returns & leverage

See full

Return on equity-47.5%-3.7pp

Debt / equity0.1×0.0×

Current ratio3.6×-0.6×

Where this comes from

Reported directly by Iovance Biotherapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The official record: Iovance Biotherapeutics, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Iovance Biotherapeutics, Inc.'s total revenue.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Iovance Biotherapeutics, Inc.'s total revenue?: Iovance Biotherapeutics, Inc. (IOVA) reported total revenue of $71.43M in Q1 2026.
How has Iovance Biotherapeutics, Inc.'s total revenue changed year-over-year?: Iovance Biotherapeutics, Inc.'s total revenue increased by 44.8% year-over-year, from $49.32M to $71.43M.
What is the long-term trend for Iovance Biotherapeutics, Inc.'s total revenue?: Over 2 years (2023 to 2025), Iovance Biotherapeutics, Inc.'s total revenue has grown at a 1388.7% compound annual growth rate (CAGR), from $1.19M to $263.5M.
What does total revenue mean?: The aggregate of all revenue from the company's operations — the top line from which all profitability metrics are derived.